IP Library Granted Patent US 8,987,340
Granted Patent B2
US 8,987,340 · App. 12/417,119 · Granted Mar 24, 2015

Sublimable sustained release delivery system and method of making same

Inventor: Richard Maskiewicz (Redlands, CA)
Assignee: Oakwood Laboratories, LLC
A61K9/0024A61K9/1617Y10S514/957
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,987,340
App. No.
12/417,119
Granted
Mar 24, 2015
Kind
B2
Abstract

The invention relates to compositions suitable for the delivery and/or stabilization of biologically active substances. The compositions comprise a sublimable matrix material and the biologically active agent to be delivered. The compositions can be used as drug delivery systems to treat a wide variety of diseases or as systems for the protection and stabilization of such substances. Also disclosed are methods for preparing compositions of the present invention.

Claims (21)

1. A method of delivering a therapeutically effective amount of a biologically active agent to treat a disease or condition in an animal in need thereof comprising:

administering to an animal a solid composition comprising at least one sublimable matrix material and a biologically active agent, wherein the sublimable matrix material is a solid phase carrier, wherein the sublimable matrix material has a melting point of about 37° C. or higher and a sublimation enthalpy from about 20 kj/mole to about 100 kj/mole;

subliming said sublimable matrix material within a body of said animal; and

sustaining release of said active agent in said animal body as a result of said subliming of said sublimable matrix material.

2. The method of claim 1 wherein said sublimable matrix material is selected from the group consisting of adamantane, hexamethylethane, perfluoroneopentane, norbornane, hexamethylcyclotrisiloxane, cyclododecane, perfluoroundecane, perfluorododecane or mixtures thereof.

3. The method of claim 1 wherein said sublimable matrix material is present in an amount of at least about 10% by weight based on the weight of the composition.

4. The method of claim 1 wherein said sublimable matrix material is present in an amount of at least about 60% by weight based on the weight of the composition.

5. The method of claim 1 wherein said sublimable matrix material is present in an amount of at least about 80% by weight based on the weight of the composition.

6. The method of claim 1 wherein said composition further contains a sublimation rate modifier.

7. The method of claim 6 comprising altering a sublimation rate of the composition as a result of said sublimation rate modifier, thereby affecting a rate of said sustained release.

8. The method of claim 6 comprising altering a surface area of the composition over time as a result of said sublimation rate modifier, thereby affecting a rate of said sustained release.

9. The method of claim 6 wherein said sublimation rate modifier is selected from the group consisting of trimethylacetamide; 2,2-dimethyl-1,3-propanediol; neopentylpivalate; perfluorodecalin; tri-tert-butylmethanol; camphor; camphene; neo-pentyl alcohol; hexachloroethane; chlorobutanol; menthol; terpin hydrate; vanillin; ethyl vanillin; 1,3,5-trioxane; naphthalene; phenol; tristearin; dextran; glycogen; tert-butanol; biodegradable polymers comprised of polylactic acid or copolymers of lactic and glycolic acids, polyorthoesters, or polyanhydrides, microparticles comprised of said biodegradable polymers; fatty acids; polyvinylpyrrolidone; polyethyleneglycol; polyvinyl alcohol; polyacrylic acid; cholesterol and microparticles thereof; caprostane; triglycerides having a melting point above 37° C.; collagen and microparticles thereof; gelatin and microparticles thereof; ethanol; propylene glycol; PEG 400; glycerol; polyglycerol; polysorbates; sucralose; sucralose pentahydrate; and mixtures thereof.

10. The method of claim 6 wherein said sublimation rate modifier is present in an amount ranging from about 0.1 to about 30% by weight based on the weight of the composition.

11. The method of claim 6 wherein said sublimation rate modifier is present in an amount ranging from about 0.5 to about 10% by weight based on the weight of the composition.

12. The method of claim 1 comprising providing the composition in a form selected from the group consisting of an implantable disk, a cylinder or a pellet, and administering said form to said animal.

13. The method of claim 1 wherein said release of said active agent is sustained for a period of at least about 7 days.

14. The method of claim 1 wherein said release of said active agent is sustained for a period of at least about 30 days.

15. The method of claim 1 wherein said release of said active agent is sustained for a period of at least about 3 months.

16. The method of claim 1 wherein the composition comprises at least two different said sublimable matrix materials.

17. The method of claim 16 wherein the composition further comprises a sublimation rate modifier.

18. The method of claim 1 wherein said animal in need thereof is a human subject.

Assignments (2)
SECURITY INTEREST Recorded May 30, 2014
From: OAKWOOD LABORATORIES, L.L.C.
To: ALFERA PHARMACEUTICALS, LLC
Reel/Frame 033070/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2011
From: MASKIEWICZ, RICHARD
To: OAKWOOD LABORATORIES, LLC
Reel/Frame 025638/0384 →
Continuity (3)
Division 11615048 · Dec 22, 2006
Provisional Application 60753114 · Dec 22, 2005
Related Publication 20090220602A1 · Sep 3, 2009